Correction: Serine protease-driven entry and S2 ' cleavage flexibility of feline coronavirus during feline enterocyte infections [0.03%]
订正：猫冠状病毒在猫肠上皮细胞感染过程中的丝氨酸蛋白酶驱动的进入和S2'裂解灵活性
Bixia Chen,Luna Vanden Buijs,Nathalie Vanderheijden et al.
Bixia Chen et al.
[This corrects the article DOI: 10.1371/journal.ppat.1013854.]. Copyright: © 2026 Chen et al. This is an open access article distributed under the terms...
Published Erratum
PLoS pathogens. 2026 May 28;22(5):e1014259. DOI:10.1371/journal.ppat.1014259 2026
Genetic analysis of pyrimidine biosynthetic enzymes in Plasmodium falciparum [0.03%]
恶性疟原虫嘧啶补救途径的遗传分析研究
Krithika Rajaram,Montana L Sievert,Rubayet Elahi et al.
Krithika Rajaram et al.
The malaria parasite Plasmodium falciparum depends entirely on de novo pyrimidine synthesis, as it is unable to salvage these essential nucleotides. This reliance makes the pyrimidine biosynthesis pathway a compelling target for antimalaria...
Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis [0.03%]
改良型抗PstS1双特异性抗体可强力抵御结核病
Akanksha,Rania Bouzeyen,Avia Watson et al.
Akanksha et al.
The role of antibodies in the host response against Mycobacterium tuberculosis (M. tb) bacteria is still poorly understood. We previously isolated two monoclonal antibodies (mAbs), p4-36 and p4-163, from an M. tb infected donor that target ...
Correction: CircRNA ARFGEF1 functions as a ceRNA to promote oncogenic KSHV-encoded viral interferon regulatory factor induction of cell invasion and angiogenesis by upregulating glutaredoxin 3 [0.03%]
订正：circRNA ARFGEF1通过上调谷氧还蛋白3促进病毒干扰素调节因子诱导细胞侵袭和血管生成的 ceRNA 功能促进致癌作用(KSHV 编码)
Shuihong Yao,Xuemei Jia,Fei Wang et al.
Shuihong Yao et al.
[This corrects the article DOI: 10.1371/journal.ppat.1009294.]. Copyright: © 2026 Yao et al. This is an open access article distributed under the terms ...
Published Erratum
PLoS pathogens. 2026 May 27;22(5):e1014267. DOI:10.1371/journal.ppat.1014267 2026
Mengyang Zhao,Leiliang Zhang
Mengyang Zhao
Enterovirus D68 (EV-D68) is an emerging pathogen associated with severe respiratory diseases and central nervous system complications. This pearl summarizes the roles of glycan receptors, such as sialic acid, and protein receptors like ICAM...
Herbert Guimaraes de Sousa Silva,Janaina de Freitas Nascimento,Marilene Souza Braga et al.
Herbert Guimaraes de Sousa Silva et al.
Trypanosoma cruzi, the etiological agent of Chagas disease, infects millions of people in the Americas. This parasite undergoes drastic changes in its morphology and metabolism between infective and noninfective forms through global remodel...
Craig R MacNair,Varnesh Tiku,Shengya Cao et al.
Craig R MacNair et al.
Outer membrane vesicles (OMVs) are nanoscale proteoliposomes shed by Gram-negative bacteria that mediate host-pathogen interactions and hold promise as platforms for vaccines and targeted drug delivery. Despite their biological and translat...
Partial or complete blocking of gD binding to HVEM affects primary and latent HSV-1 infection as well as eye disease in HSV-1 infected mice [0.03%]
gD结合HVEM的部分或完全阻断影响HSV-1感染的小鼠的一次性及潜伏感染以及眼部疾病
Deepak Arya,Ujjaldeep Jaggi,Jay J Oh et al.
Deepak Arya et al.
Herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) engages herpesvirus entry mediator (HVEM) and other cellular receptors to mediate efficient viral attachment. We recently identified gD amino acids (aa) Q27-T29 as critical to complete...
Characterization of inner capsid σA protein as a virulence factor of the pteropine orthoreovirus [0.03%]
非洲猪瘟病毒衣壳内部σA蛋白是一种致病因子
Hayato Harima,Michihito Sasaki,Takuma Ariizumi et al.
Hayato Harima et al.
Pteropine orthoreovirus (PRV) is an emerging zoonotic virus that causes pneumonia in humans. We previously isolated the PRV strain Nachunsulwe-57 (N57) from a Zambian fruit bat and demonstrated its low virulence in laboratory mice. Here, we...
PrP turnover in vivo and the time to effect of prion disease therapeutics [0.03%]
朊病毒病治疗药物起效时间及体内PrP蛋白周转率
Taylor L Corridon,Jill O&#x;Moore,Alyssa Seerley et al.
Taylor L Corridon et al.
PrP lowering is effective against prion disease in animal models and is being tested clinically. Therapies in the current pipeline lower PrP production, leaving pre-existing PrP to be cleared according to its own half-life. We hypothesized ...